My take of the Dec. 7th CC. Not much new but what was

New Post Public Reply Private Reply Replies (2) Message Board
ohm20
839
My take of the Dec. 7th CC.

Not much new but what was already known was well presented.

But the one thing new is a wondrous thing. The results from the one macaque treated with AAV leronlimab is even greater than it appears. A functional cure for HIV would be amazing. What about other long term diseases Long Covid, ME/CFS, Alzheimer's, Parkinson's, ALS, diabetes, recurrent cancers and so many more. Only one shot to help long suffering patients would be a blessing.

With just one subject in the study only scientists and doctors focusing on HIV are paying attention. Once a multi-subject study is done and the clinical holds are lifted proving safety that news should become widespread on HIV.

The future: The downside is that very long term HIV trials would need to be conducted to prove out safety in a drug that completely alters the immune system. Meanwhile Cytodyn can conduct it's other trials, gain approval and build up a war chest on it's 2031 expiration patent. Part of that war chest can be used to license the AAV patent from OHSU and will have further protection via that patent farther into the future.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Bunge Limited Faces Market Pressures with Stock Drop

Updated Category News Views 262

Bunge Limited Faces Market Pressures as Stock Prices Decline In a year characterized by considerable market fluctuations, Bunge Limited (NYSE: BG) has seen its stock reach a concerning 52-week low of $77.52. With an attractive price-to-earnings (P/E) ratio of 9.7 and a commendable dividend yield of 3.48%, Bunge has consistently paid dividends for an impressive 24 years,...

Continue Reading
Key Market Events to Monitor This Coming Week

Updated Category News Views 511

Upcoming Market Highlights to Observe As we look ahead, several significant events are poised to influence market dynamics. As corporate earnings season blossoms, attention will focus on major players in tech, finance and energy sectors. Global leaders are gathering to discuss critical economic issues, all while fluctuating oil prices add to the tension. Let's explore...

Continue Reading
Touchmark Bancshares: OCC Agreement Axed, What’s Next?

Updated Category News Views 159

Touchmark Bancshares, Inc. just cut ties with the Office of the Comptroller of the Currency (OCC) on February 17, 2026, after a lengthy 22-month oversight period. This enforcement action was slapped on them back in April 2024, and it seemed like a cloud hanging over their heads for ages. Traders were watching closely—this termination isn’t just a footnote; it speaks...

Continue Reading
Bybit Unveils Inclusive WSOT 2025 with Massive Prize Pool

Updated Category News Views 531

Bybit Kicks Off an Innovative WSOT 2025 Bybit, a leading player in the cryptocurrency exchange arena, is taking bold steps to redefine the World Series of Trading (WSOT) in its upcoming 2025 edition. Known for hosting the longest-running crypto trading competition globally, Bybit is set to catapult this event into a new era, offering a staggering 10 million USDT prize...

Continue Reading
Brookfield Corporation Announces Q2 2025 Earnings Call Details

Updated Category News Views 396

Brookfield Corporation to Host Second Quarter 2025 Results Conference Call BROOKFIELD, NEWS — Brookfield Corporation (NYSE: BN) will host its second quarter 2025 conference call and webcast on Thursday, August 7, 2025, at 10:00 AM (ET). Key Information and Joining Details Results from the financial quarter will be released that morning around 7:00 AM (ET) and will be...

Continue Reading